These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 36041790)

  • 21. [Renal anemia and hypoxia-inducible factor prolyl hydroxylase inhibitor].
    Maruno S; Tanaka T; Nangaku M
    Rinsho Ketsueki; 2021; 62(5):371-377. PubMed ID: 34108317
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vadadustat in Patients with Anemia and Non-Dialysis-Dependent CKD.
    Chertow GM; Pergola PE; Farag YMK; Agarwal R; Arnold S; Bako G; Block GA; Burke S; Castillo FP; Jardine AG; Khawaja Z; Koury MJ; Lewis EF; Lin T; Luo W; Maroni BJ; Matsushita K; McCullough PA; Parfrey PS; Roy-Chaudhury P; Sarnak MJ; Sharma A; Spinowitz B; Tseng C; Tumlin J; Vargo DL; Walters KA; Winkelmayer WC; Wittes J; Eckardt KU;
    N Engl J Med; 2021 Apr; 384(17):1589-1600. PubMed ID: 33913637
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nonclinical Characterization of the Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat, a Novel Treatment of Anemia of Chronic Kidney Disease.
    Del Balzo U; Signore PE; Walkinshaw G; Seeley TW; Brenner MC; Wang Q; Guo G; Arend MP; Flippin LA; Chow FA; Gervasi DC; Kjaergaard CH; Langsetmo I; Guenzler V; Liu DY; Klaus SJ; Lin A; Neff TB
    J Pharmacol Exp Ther; 2020 Aug; 374(2):342-353. PubMed ID: 32487538
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Are all erythropoiesis-stimulating agents created equal?
    Locatelli F; Del Vecchio L; De Nicola L; Minutolo R
    Nephrol Dial Transplant; 2021 Jul; 36(8):1369-1377. PubMed ID: 32206785
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Roxadustat in the treatment of anaemia in chronic kidney disease.
    Del Vecchio L; Locatelli F
    Expert Opin Investig Drugs; 2018 Jan; 27(1):125-133. PubMed ID: 29254377
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease.
    Pergola PE; Spinowitz BS; Hartman CS; Maroni BJ; Haase VH
    Kidney Int; 2016 Nov; 90(5):1115-1122. PubMed ID: 27650732
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of HIF prolyl-hydroxylase inhibitor vs epoetin and darbepoetin for anemia in chronic kidney disease patients not undergoing dialysis: A network meta-analysis.
    Zheng Q; Yang H; Sun L; Wei R; Fu X; Wang Y; Huang Y; Liu YN; Liu WJ
    Pharmacol Res; 2020 Sep; 159():105020. PubMed ID: 32561478
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Three Times Weekly Dosing of Daprodustat versus Conventional Epoetin for Treatment of Anemia in Hemodialysis Patients: ASCEND-TD: A Phase 3 Randomized, Double-Blind, Noninferiority Trial.
    Coyne DW; Singh AK; Lopes RD; Bailey CK; DiMino TL; Huang C; Connaire J; Rastogi A; Kim SG; Orias M; Shah S; Patel V; Cobitz AR; Wanner C
    Clin J Am Soc Nephrol; 2022 Sep; 17(9):1325-1336. PubMed ID: 35918106
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A spotlight on using HIF-PH inhibitors in renal anemia.
    Odawara M; Nishi H; Nangaku M
    Expert Opin Pharmacother; 2024 Jul; 25(10):1291-1299. PubMed ID: 38994698
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hypoxia-inducible factor prolyl hydroxylase inhibitors for anaemia in chronic kidney disease: a clinical practice document by the European Renal Best Practice board of the European Renal Association.
    Stoumpos S; Crowe K; Sarafidis P; Barratt J; Bolignano D; Del Vecchio L; Małyszko J; Więcek A; Ortiz A; Cozzolino M
    Nephrol Dial Transplant; 2024 Sep; 39(10):1710-1730. PubMed ID: 38573822
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluating the safety and efficacy of vadadustat for the treatment of anemia associated with chronic kidney disease.
    Mimura I; Tanaka T; Nangaku M
    Expert Opin Pharmacother; 2024 Jun; 25(9):1111-1120. PubMed ID: 38896547
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of Anemia Associated with Chronic Kidney Disease: Plea for Considering Physiological Erythropoiesis.
    Kuragano T
    Int J Mol Sci; 2024 Jul; 25(13):. PubMed ID: 39000429
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hypoxia-Inducible Factor-Prolyl Hydroxylase Domain Inhibitors to Treat Anemia in Chronic Kidney Disease.
    Sakashita M; Tanaka T; Nangaku M
    Contrib Nephrol; 2019; 198():112-123. PubMed ID: 30991411
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors in Kidney Disease.
    Ha JT; Hiremath S; Jun M; Green SC; Wheeler DC; Coyne DW; Perkovic V; Badve SV
    NEJM Evid; 2024 Sep; 3(9):EVIDoa2300189. PubMed ID: 39186635
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hypoxia-Inducible Factor Activators in Renal Anemia: Current Clinical Experience.
    Sanghani NS; Haase VH
    Adv Chronic Kidney Dis; 2019 Jul; 26(4):253-266. PubMed ID: 31477256
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enarodustat to treat anemia in chronic kidney disease.
    Fukui K; Tanaka T; Nangaku M
    Drugs Today (Barc); 2021 Aug; 57(8):491-497. PubMed ID: 34405206
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and Efficacy of Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitors vs. Erythropoietin-Stimulating Agents in Treating Anemia in Renal Patients (With or Without Dialysis): A Meta-Analysis and Systematic Review.
    Damarlapally N; Thimmappa V; Irfan H; Sikandari M; Madhu K; Desai A; Pavani P; Zakir S; Gupta M; Khosa MM; Kotak S; Varrassi G; Khatri M; Kumar S
    Cureus; 2023 Oct; 15(10):e47430. PubMed ID: 38021836
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An updated meta-analysis on the efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitor treatment of anemia in nondialysis-dependent chronic kidney disease.
    Zhao H; Li P; Zhang HL; Jia L
    Ren Fail; 2023; 45(2):2258986. PubMed ID: 37724564
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and Safety of Daprodustat Compared with Darbepoetin Alfa in Japanese Hemodialysis Patients with Anemia: A Randomized, Double-Blind, Phase 3 Trial.
    Akizawa T; Nangaku M; Yonekawa T; Okuda N; Kawamatsu S; Onoue T; Endo Y; Hara K; Cobitz AR
    Clin J Am Soc Nephrol; 2020 Aug; 15(8):1155-1165. PubMed ID: 32723804
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical Trial of Vadadustat in Patients with Anemia Secondary to Stage 3 or 4 Chronic Kidney Disease.
    Martin ER; Smith MT; Maroni BJ; Zuraw QC; deGoma EM
    Am J Nephrol; 2017; 45(5):380-388. PubMed ID: 28343225
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.